References
- Cubicin (daptomycin) injection [package insert]. Lexington, MA: Cubist Pharmaceuticals; 2013.
- Odero RO, Cleveland KO, Gelfand MS. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. J Antimicrob Chemother 2009;63:1299–300.
- Papadopoulos S, Ball AM, Liewer SE, Martin CA, Winstead PS, Murphy BS. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006;42:e108–10.
- Echevarria K, Datta P, Cadena J, Lewis JS II. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 2005;55:599–600.
- Patel SJ, Samo TC, Suki WN. Early-onset rhabdomyolysis related to daptomycin use. Int J Antimicrob Agents 2007; 30:472–4.
- LiverTox. United States National Library of Medicine. Bethesda, MD: NLM; 2014. Available at: http://livertox.nih.gov/ (accessed 11 February 2014).
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.
- Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664–9.
- Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother 2006;57:578–9.
- Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007;51:2741–7.
- Bookstaver PB, Bland CM, Qureshi ZP, Faulkner-Fennell CM, Sheldon MA, Caulder CR, et al. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Pharmacotherapy 2013;33:1322–30.
- Abraham G, Finkelberg D, Spooner LM. Daptomycin- induced acute renal and hepatic toxicity without rhabdomyolysis. Ann Pharmacother 2008;42:719–21.
- Colomba C, Rubino R, Siracusa L, Mazzola G, Titone L. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C. J Antimicrob Chemother 2012;67: 249–50.
- Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 2004;150:137–47.